The median delay between first symptoms and a CTCL diagnosis is measured in years, because early CTCL looks like ordinary dermatitis and is treated as such. The Dupixent lawsuits add a layer: the drug clears inflammatory skin so effectively that, plaintiffs allege, it can hide the lymphoma beneath. This is general awareness information, not medical advice. Your dermatologist is the person to talk to.
Patterns that differ from typical eczema
Location. Eczema favors flexural areas — elbows, knees, neck, hands. Early CTCL often appears in sun-protected areas: buttocks, inner thighs, trunk, under the breasts.
Shape and texture. Persistent, well-defined patches or plaques that don't shift with flares. Wrinkled, "cigarette paper" surface. Patches that thicken over months rather than coming and going.
Response. Lesions that do not clear with treatments that used to work, or that clear and return in the same spots, or new lesions appearing while overall skin improves on Dupixent.
Beyond the skin. Swollen lymph nodes, unexplained weight loss, night sweats, or whole-body redness (erythroderma).
One skin biopsy — sometimes several — is the only way to distinguish CTCL from eczema. Patients in the litigation describe years of dose adjustments before anyone ordered one.
Direct2Attorney · Health AwarenessWhat to ask
Before starting Dupixent
Reasonable questions- Has CTCL been ruled out for my long-standing "eczema"?
- Should I have a baseline biopsy of a representative lesion?
- What changes would prompt re-evaluation?
- Are there reasons I'm at higher risk?
While on Dupixent
If skin changes- Can this new pattern be biopsied?
- Are my lymph nodes enlarged?
- Should I see a cutaneous lymphoma specialist?
- Would a pause in treatment be appropriate to evaluate?
Documenting skin changes
Photograph lesions monthly with a coin for scale and consistent lighting. Note dates when new patches appear and how they respond. Keep records of every dermatology visit and the treatments tried. If a biopsy is eventually done, this record helps establish when the disease was present — which matters medically for staging and legally for any claim.
Why this is in the lawsuits
Plaintiffs allege the Dupixent label should have recommended CTCL screening before and during treatment, given the overlap between the conditions and the signal in adverse event data. Whether the manufacturers had that duty is the central question in MDL 3180.
What this means if you're considering a claim
If you were on Dupixent and were subsequently diagnosed with CTCL, the delay in diagnosis and the stage at diagnosis are both relevant to a claim. A free review can evaluate your situation. If you have symptoms without a diagnosis, see a dermatologist first; the legal question follows the medical one.
Diagnosed with CTCL after Dupixent?
Free, confidential review. No obligation.
Common Questions
Early-stage CTCL is often controlled for many years with skin-directed therapy. Advanced disease is harder to treat. Early diagnosis matters.
No. But some reports describe lesions becoming more apparent after stopping, aiding diagnosis. Discuss with your specialist.
Anyone with a confirmed or suspected CTCL diagnosis. Academic centers typically have dedicated clinics.
Generally no. It is not considered an inherited cancer.
No. Direct2Attorney’s review is free, and participating law firms typically work on contingency, meaning fees are generally paid only if there is a recovery. Confirm fee terms in writing with the firm.
